Journal of the Formosan Medical Association (Apr 2021)
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
- Yu-Yun Shao,
- Shen-Yung Wang,
- Shi-Ming Lin,
- Kuan-Yang Chen,
- Jeng-Hwei Tseng,
- Ming-Chih Ho,
- Rheun-Chuan Lee,
- Po-Chin Liang,
- Li-Ying Liao,
- Kai-Wen Huang,
- Jui-Ting Hu,
- Ja-Der Liang,
- Shen-Yung Wang,
- Kwong-Ming Kee,
- Chih-Lin Lin,
- Shi-Ming Lin,
- Chung-Kwe Wang,
- Sheng-Nan Lu,
- Jing-Houng Wang,
- Wei-Chen Lee,
- Chien-Hung Chen,
- Chun-Jen Liu,
- Yi-Hsiang Huang,
- Chia-Chi Wang,
- Tsang-En Wang,
- Po-Heng Chuang,
- Chia-Yen Dai,
- Chiun Hsu,
- Yu-Yun Shao,
- San-Chi Chen,
- Chia-Hsun Hsieh
Affiliations
- Yu-Yun Shao
- Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
- Shen-Yung Wang
- Division of Gastroenterology and Hepatology, Department of Medicine, MacKay Memorial Hospital, Taipei, Taiwan
- Shi-Ming Lin
- Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Division of Gastroenterology and Hepatology, Department of Medicine, MacKay Memorial Hospital, Taipei, Taiwan; Corresponding author. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, 199, Tung Hwa North Road, Taipei, 105, Taiwan. Fax: +886 3 3282824.
- Kuan-Yang Chen
- Renai Branch, Taipei City Hospital, Taipei, Taiwan
- Jeng-Hwei Tseng
- Chang Gung Memorial Hospital, Linkuo, Taiwan
- Ming-Chih Ho
- National Taiwan University Hospital, Taipei, Taiwan
- Rheun-Chuan Lee
- Taipei Veterans General Hospital, Taipei, Taiwan
- Po-Chin Liang
- National Taiwan University Hospital, Taipei, Taiwan
- Li-Ying Liao
- Renai Branch, Taipei City Hospital, Taipei, Taiwan
- Kai-Wen Huang
- National Taiwan University Hospital, Taipei, Taiwan
- Jui-Ting Hu
- Cathay General Hospital, Taipei, Taiwan
- Ja-Der Liang
- National Taiwan University Hospital, Taipei, Taiwan
- Shen-Yung Wang
- MacKay Memorial Hospital, Taipei, Taiwan
- Kwong-Ming Kee
- Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
- Chih-Lin Lin
- Renai Branch, Taipei City Hospital, Taipei, Taiwan
- Shi-Ming Lin
- Chang Gung Memorial Hospital, Linkuo, Taiwan
- Chung-Kwe Wang
- Kang Ning Hospital, Taipei, Taiwan
- Sheng-Nan Lu
- Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
- Jing-Houng Wang
- Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
- Wei-Chen Lee
- Chang Gung Memorial Hospital, Linkuo, Taiwan
- Chien-Hung Chen
- National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
- Chun-Jen Liu
- National Taiwan University Hospital, Taipei, Taiwan
- Yi-Hsiang Huang
- Taipei Veterans General Hospital, Taipei, Taiwan
- Chia-Chi Wang
- Taipei Tzu Chi Hospital, Taipei, Taiwan
- Tsang-En Wang
- MacKay Memorial Hospital, Taipei, Taiwan
- Po-Heng Chuang
- China Medical University Hospital, Taichung, Taiwan
- Chia-Yen Dai
- Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- Chiun Hsu
- National Taiwan University Hospital, Taipei, Taiwan
- Yu-Yun Shao
- National Taiwan University Hospital, Taipei, Taiwan
- San-Chi Chen
- Taipei Veterans General Hospital, Taipei, Taiwan
- Chia-Hsun Hsieh
- Chang Gung Memorial Hospital, Linkuo, Taiwan
- Journal volume & issue
-
Vol. 120,
no. 4
pp. 1051 – 1060
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.
